MX2013004584A - Composicion que comprende 2-metilpropanotioato de s-[2-([[1-(2-etilbutil)-ciclohexil]-carbonil]amino)fenil] y croscarmelosa de sodio. - Google Patents
Composicion que comprende 2-metilpropanotioato de s-[2-([[1-(2-etilbutil)-ciclohexil]-carbonil]amino)fenil] y croscarmelosa de sodio.Info
- Publication number
- MX2013004584A MX2013004584A MX2013004584A MX2013004584A MX2013004584A MX 2013004584 A MX2013004584 A MX 2013004584A MX 2013004584 A MX2013004584 A MX 2013004584A MX 2013004584 A MX2013004584 A MX 2013004584A MX 2013004584 A MX2013004584 A MX 2013004584A
- Authority
- MX
- Mexico
- Prior art keywords
- ethylbutyl
- cyclohexyl
- phenyl
- amino
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se relaciona a una composición que comprende: a) 2-metilpropanotioato de S-[2-([(1-(2-etilbutil)-cicl ohexil]-carbonil]amino)fenilo] y b) croscarmelosa de sodio. La presente invención también se relaciona con un proceso para la preparación de una composición que comprende los siguientes pasos: a) mezclar y granular el 2-metilpropanotioato de S-[2-([[1-(2-etilbutil)-ciclohexil]-carbonil] amino)fenilo], crospovidona, celulosa microcristalina, croscarmelosa de sodio e hidroxipropilmetilcelulosa; b) pulverizar hasta el 0.5 en peso de HPMC en agua o en 10%-30% de etanol en peso/70%-90% de agua en peso, sobre los gránulos obtenidos en el paso a); c) secar el granulado; y d) mezclar la celulosa microcristalina, dióxido de silicio coloidal y estearilfumarato de sodio con el granulad seco obtenido en el paso c).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10190045 | 2010-11-04 | ||
| PCT/EP2011/069087 WO2012059447A1 (en) | 2010-11-04 | 2011-10-31 | A composition comprising s-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate and croscarmellose sodium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013004584A true MX2013004584A (es) | 2013-05-17 |
| MX345650B MX345650B (es) | 2017-02-09 |
Family
ID=43759428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013004584A MX345650B (es) | 2010-11-04 | 2011-10-31 | Composicion que comprende 2-metilpropanotioato de s- [2 -( [ [1-(2-etilbutil) -ciclohexil] -carbonil]amino) fenil] y croscarmelosa de sodio. |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9107836B2 (es) |
| EP (1) | EP2635263B1 (es) |
| JP (1) | JP5676005B2 (es) |
| KR (1) | KR101579659B1 (es) |
| CN (2) | CN105833283A (es) |
| AR (1) | AR083693A1 (es) |
| BR (1) | BR112013010704B8 (es) |
| CA (1) | CA2815280C (es) |
| CL (1) | CL2013001164A1 (es) |
| CR (1) | CR20130181A (es) |
| EA (1) | EA025649B1 (es) |
| EC (1) | ECSP13012603A (es) |
| ES (1) | ES2553279T3 (es) |
| IL (1) | IL225780B (es) |
| MA (1) | MA34643B1 (es) |
| MX (1) | MX345650B (es) |
| MY (1) | MY164729A (es) |
| NZ (1) | NZ609529A (es) |
| PE (1) | PE20140018A1 (es) |
| SG (1) | SG190025A1 (es) |
| TW (1) | TWI507192B (es) |
| UA (1) | UA110117C2 (es) |
| WO (1) | WO2012059447A1 (es) |
| ZA (1) | ZA201302954B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2768091T3 (es) | 2009-02-10 | 2020-06-19 | Amarin Pharmaceuticals Ie Ltd | Uso del éster etílico del ácido eicosapentaenoico para tratar la hipertrigliceridemia |
| PT2978859T (pt) | 2013-03-27 | 2018-10-04 | Hoffmann La Roche | Marcadores genéticos para previsão da capacidade de resposta à terapêutica |
| JP5871984B2 (ja) * | 2013-04-15 | 2016-03-01 | 株式会社三和化学研究所 | オルメサルタンメドキソミルを含有する医薬組成物 |
| MX2016005505A (es) | 2013-12-19 | 2016-07-22 | Hoffmann La Roche | Modulador de la proteina de transferencia de ester de colesterilo (cetp) para usarse en el tratamiento de enfermedades oculares. |
| MX2017000582A (es) | 2014-07-30 | 2017-04-27 | Hoffmann La Roche | Marcadores geneticos para predecir la reactividad a terapia con agente que eleva la lipoproteina de alta densidad (hdl) o que imita la lipoproteina de alta densidad (hdl). |
| CN104434913A (zh) * | 2014-12-20 | 2015-03-25 | 长沙佰顺生物科技有限公司 | 一种安塞曲匹药物组合物及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2894445B2 (ja) | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Ｃｅｔｐ活性阻害剤として有効な化合物 |
| US7208465B2 (en) * | 2000-11-03 | 2007-04-24 | The Procter & Gamble Company | Methods and compositions for improved fragrancing of a surface |
| ATE389396T1 (de) * | 2002-12-20 | 2008-04-15 | Pfizer Prod Inc | Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer |
| BRPI0408442A (pt) | 2003-03-17 | 2006-04-04 | Japan Tobacco Inc | método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato |
| NZ542852A (en) | 2003-03-17 | 2008-09-26 | Japan Tobacco Inc | Pharmaceutical compositions of CETP inhibitors |
| CA2534371A1 (en) * | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| US20080138428A1 (en) * | 2005-01-28 | 2008-06-12 | Pfizer Inc. | Fast-Disintegrating Microporous Binders |
| US7435849B2 (en) | 2005-10-31 | 2008-10-14 | Hoffmann-La Roche Inc. | Process for the production of acid chlorides |
| EP1935867A1 (en) | 2006-12-20 | 2008-06-25 | F. Hoffmann-La Roche Ag | Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid |
| MX2011005304A (es) * | 2008-12-08 | 2011-06-01 | Hoffmann La Roche | Administracion combinada de farmaco. |
| US20110004011A1 (en) | 2009-07-01 | 2011-01-06 | Declan Costello | Novel process |
-
2011
- 2011-10-31 BR BR112013010704A patent/BR112013010704B8/pt active IP Right Grant
- 2011-10-31 MY MYPI2013700710A patent/MY164729A/en unknown
- 2011-10-31 SG SG2013032123A patent/SG190025A1/en unknown
- 2011-10-31 CN CN201610309140.6A patent/CN105833283A/zh active Pending
- 2011-10-31 WO PCT/EP2011/069087 patent/WO2012059447A1/en active Application Filing
- 2011-10-31 CA CA2815280A patent/CA2815280C/en active Active
- 2011-10-31 ES ES11776201.3T patent/ES2553279T3/es active Active
- 2011-10-31 CN CN2011800532370A patent/CN103200935A/zh active Pending
- 2011-10-31 MX MX2013004584A patent/MX345650B/es active IP Right Grant
- 2011-10-31 EP EP11776201.3A patent/EP2635263B1/en active Active
- 2011-10-31 KR KR1020137014214A patent/KR101579659B1/ko active IP Right Grant
- 2011-10-31 JP JP2013537093A patent/JP5676005B2/ja active Active
- 2011-10-31 UA UAA201306203A patent/UA110117C2/uk unknown
- 2011-10-31 PE PE2013000910A patent/PE20140018A1/es not_active Application Discontinuation
- 2011-10-31 NZ NZ609529A patent/NZ609529A/en unknown
- 2011-10-31 EA EA201390622A patent/EA025649B1/ru not_active IP Right Cessation
- 2011-11-03 TW TW100140194A patent/TWI507192B/zh not_active IP Right Cessation
- 2011-11-03 AR ARP110104077A patent/AR083693A1/es unknown
- 2011-11-03 US US13/288,082 patent/US9107836B2/en active Active
-
2013
- 2013-04-15 IL IL225780A patent/IL225780B/en active IP Right Grant
- 2013-04-23 ZA ZA2013/02954A patent/ZA201302954B/en unknown
- 2013-04-24 CR CR20130181A patent/CR20130181A/es unknown
- 2013-04-29 CL CL2013001164A patent/CL2013001164A1/es unknown
- 2013-05-03 EC ECSP13012603 patent/ECSP13012603A/es unknown
- 2013-05-03 MA MA35868A patent/MA34643B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX345650B (es) | Composicion que comprende 2-metilpropanotioato de s- [2 -( [ [1-(2-etilbutil) -ciclohexil] -carbonil]amino) fenil] y croscarmelosa de sodio. | |
| CL2007002949A1 (es) | Forma cristalina del compuesto 2-cloro-5-(3,6-dihidro-3-metil-2,6-dioxo-4-(trifluorometil)-1-(2h)-pirimidinil)-4-fluoro-n-((metil(1-metiletil)amino)sulfonil)benzamida; proceso para la preparacion de dicha forma cristalina; composicion fitoprotectora; | |
| UA104590C2 (ru) | Капсулированная лекарственная форма, содержащая суспензионную композицию производной индолинона | |
| TW200643013A (en) | Pyrazoles | |
| NZ716487A (en) | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide | |
| NZ600207A (en) | Substituted 4-aminocyclohexane derivatives | |
| ATE551328T1 (de) | Neuartige 5-substituierte hydantoine | |
| JO2973B1 (en) | Fumarate salt for (alpha-beta-R) -6-bromo-alpha-[2- (methylamino) ethyl-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinoline ethanol | |
| MX2009006865A (es) | Proceso para la preparacion de compuestos 6,6-dimetil-3-aza-bicicl o-[3.1.0]-hexano utilizando intermediario bisulfitico. | |
| MX2009005048A (es) | Nuevo proceso para la preparacion de derivados de 2-imino-tiazolidin-4-ona. | |
| NZ599254A (en) | Novel vanilloid receptor ligands and the use thereof for the production of pharmaceuticals | |
| NZ600231A (en) | Pharmaceutical compositions comprising sigma receptor ligands | |
| MX2012005329A (es) | Compuestos benzoimidazolicos y sus usos. | |
| EA200900707A1 (ru) | Новый способ синтеза 7,8-диметокси-1,3-дигидро-2h-3-бензазепин-2-она, и его применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой | |
| MX2010008713A (es) | Derivados de 5,6-bisaril-2-piridina-carboxamida, su preparacion y su aplicacion en terapeutica como antagonistas de los receptores de la urotensina ii. | |
| JO2749B1 (en) | Indole-2-Wen derivatives bilaterally substituted at position 3, their preparation and therapeutic application | |
| WO2012161497A3 (ko) | 보습능이 우수한 펩타이드 유도체 및 이의 용도 | |
| NO20093039L (no) | Indolizineddiksyrederivater som CRTH2 antagonister | |
| WO2010041277A3 (en) | Stable pharmaceutical compositions of montelukast or its salts or solvates or hydrates | |
| RU2014119866A (ru) | Твердые дозированные формы (s)-этил 2-амино-3-(2-амино-6(r)-1-(4-хлор-2-(3-метил-1н-пиразол-1-ил)фенил)-2,2,2-трифторэтокси)пиримидин-4-ил)фенил)пропаноата | |
| WO2011084434A3 (en) | Aza-ring fused indole and indoline derivatives | |
| WO2011085033A3 (en) | Dp2 antagonist and uses thereof | |
| MX2013006031A (es) | Formulacion liposomal de dalcetrapib. | |
| NZ619257A (en) | Ketamine derivatives | |
| JP2010527364A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |